Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30(+) Lymphoma

Brentuximab vedotin is an antibody-conjugated chemotherapy targeting CD30 indicated in treatment of several lymphomas. We report the first 3 cases of cytomegalovirus severe infections with retinitis following this treatment. Evolution was favorable, but relapse occurred after treatment rechallenge....

Descripción completa

Detalles Bibliográficos
Autores principales: Tudesq, Jean-Jacques, Vincent, Laure, Lebrun, Julie, Hicheri, Yosr, Gabellier, Ludovic, Busetto, Timothé, Merle, Corinne, Fegueux, Nathalie, Ceballos, Patrice, Quittet, Philippe, Navarro, Robert, Hillaire-Buys, Dominique, Cartron, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473439/
https://www.ncbi.nlm.nih.gov/pubmed/28638848
http://dx.doi.org/10.1093/ofid/ofx091
Descripción
Sumario:Brentuximab vedotin is an antibody-conjugated chemotherapy targeting CD30 indicated in treatment of several lymphomas. We report the first 3 cases of cytomegalovirus severe infections with retinitis following this treatment. Evolution was favorable, but relapse occurred after treatment rechallenge. We suggest vigilance about cytomegalovirus in patients treated with brentuximab vedotin.

Ejemplares similares